Hikma Has A First With Labetalol Launch In US
Also Introduces Hydralazine And Estradiol Valerate As Part Of Latest Injectables Push
Hikma says it is breaking new ground in the US with a ready-to-use presentation of labetalol. Meanwhile, the company has also added hydralazine to its list of recent injectables launches.
You may also be interested in...
Hikma has added three products – a generic version of Banzel tablets and injectables ganciclovir and doxycycline – to its US portfolio.
Fresh from resuming launch of its generic version of Advair in the US, Hikma has also been boosted by an FDA approval for its 505(b)(2) naloxone 8mg nasal spray. Both developments are expected to drive the firm’s generics business to the top end of its guidance for 2021, management revealed.
Hyloris has secured Hikma as its US marketing partner for Maxigesic IV. The deal gives Hyloris access to Hikma’s presence in complex, injectable hospital products while aligning with Hikma’s push into differentiated treatments.